FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904062731> ?p ?o ?g. }

• W2904062731 endingPage "205521731881903" @default.
• W2904062731 startingPage "205521731881903" @default.
• W2904062731 abstract "Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings.To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide).Patients from an administrative claims database (1 Jan 2012-31 Dec 2015) were selected if they: were 18-63 years old; had an MS diagnosis; had newly initiated sc IFNβ-1a, dimethyl fumarate, fingolimod, or teriflunomide (first claim = index); had no evidence of DMD 12-months pre-index; and had 12-month eligibility pre- and post-index. Relapse was defined as an MS-related inpatient stay, emergency room visit, or outpatient visit with a corticosteroid prescription ± 7 days. Outcomes were evaluated using logistic regression and generalized linear models.A total of 4475 patients met inclusion criteria: 21.9% sc IFNβ-1a, 51.0% dimethyl fumarate, 19.7% fingolimod, 7.4% teriflunomide. Teriflunomide patients had 1.357 (95% CI 1.000, 1.831; p = 0.0477) greater odds of 1-year relapse than sc IFNβ-1a patients. Estimated mean all-cause 1-year costs were higher after fingolimod (US$72,376) v. sc IFNβ-1a initiation (US$65,408; p < 0.0001). Non-DMD costs were not significantly different.Patients initiating sc IFNβ-1a had better relapse outcomes v. teriflunomide, and lower all-cause costs v. fingolimod." @default.
• W2904062731 created "2018-12-22" @default.
• W2904062731 creator A5010370202 @default.
• W2904062731 creator A5032537687 @default.
• W2904062731 creator A5050509909 @default.
• W2904062731 creator A5064084228 @default.
• W2904062731 date "2018-10-01" @default.
• W2904062731 modified "2023-10-17" @default.
• W2904062731 title "A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs" @default.
• W2904062731 cites W130665911 @default.
• W2904062731 cites W1982508920 @default.
• W2904062731 cites W2012579017 @default.
• W2904062731 cites W2014094373 @default.
• W2904062731 cites W2061326496 @default.
• W2904062731 cites W2067338532 @default.
• W2904062731 cites W2072173083 @default.
• W2904062731 cites W2093005278 @default.
• W2904062731 cites W2129168200 @default.
• W2904062731 cites W2138992948 @default.
• W2904062731 cites W2154217034 @default.
• W2904062731 cites W2159411766 @default.
• W2904062731 cites W2169490447 @default.
• W2904062731 cites W2171614089 @default.
• W2904062731 cites W2196420394 @default.
• W2904062731 cites W2327609249 @default.
• W2904062731 cites W2498119267 @default.
• W2904062731 cites W2587994165 @default.
• W2904062731 cites W2744488360 @default.
• W2904062731 cites W2756171169 @default.
• W2904062731 doi "https://doi.org/10.1177/2055217318819031" @default.
• W2904062731 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6299291" @default.
• W2904062731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30574342" @default.
• W2904062731 hasPublicationYear "2018" @default.
• W2904062731 type Work @default.
• W2904062731 sameAs 2904062731 @default.
• W2904062731 citedByCount "4" @default.
• W2904062731 countsByYear W29040627312019 @default.
• W2904062731 countsByYear W29040627312021 @default.
• W2904062731 countsByYear W29040627312022 @default.
• W2904062731 crossrefType "journal-article" @default.
• W2904062731 hasAuthorship W2904062731A5010370202 @default.
• W2904062731 hasAuthorship W2904062731A5032537687 @default.
• W2904062731 hasAuthorship W2904062731A5050509909 @default.
• W2904062731 hasAuthorship W2904062731A5064084228 @default.
• W2904062731 hasBestOaLocation W29040627311 @default.
• W2904062731 hasConcept C126322002 @default.
• W2904062731 hasConcept C151956035 @default.
• W2904062731 hasConcept C156957248 @default.
• W2904062731 hasConcept C160735492 @default.
• W2904062731 hasConcept C162324750 @default.
• W2904062731 hasConcept C203014093 @default.
• W2904062731 hasConcept C2426938 @default.
• W2904062731 hasConcept C2776036978 @default.
• W2904062731 hasConcept C2776819417 @default.
• W2904062731 hasConcept C2777703276 @default.
• W2904062731 hasConcept C2778577042 @default.
• W2904062731 hasConcept C2779134260 @default.
• W2904062731 hasConcept C2780640218 @default.
• W2904062731 hasConcept C50522688 @default.
• W2904062731 hasConcept C71924100 @default.
• W2904062731 hasConcept C98274493 @default.
• W2904062731 hasConceptScore W2904062731C126322002 @default.
• W2904062731 hasConceptScore W2904062731C151956035 @default.
• W2904062731 hasConceptScore W2904062731C156957248 @default.
• W2904062731 hasConceptScore W2904062731C160735492 @default.
• W2904062731 hasConceptScore W2904062731C162324750 @default.
• W2904062731 hasConceptScore W2904062731C203014093 @default.
• W2904062731 hasConceptScore W2904062731C2426938 @default.
• W2904062731 hasConceptScore W2904062731C2776036978 @default.
• W2904062731 hasConceptScore W2904062731C2776819417 @default.
• W2904062731 hasConceptScore W2904062731C2777703276 @default.
• W2904062731 hasConceptScore W2904062731C2778577042 @default.
• W2904062731 hasConceptScore W2904062731C2779134260 @default.
• W2904062731 hasConceptScore W2904062731C2780640218 @default.
• W2904062731 hasConceptScore W2904062731C50522688 @default.
• W2904062731 hasConceptScore W2904062731C71924100 @default.
• W2904062731 hasConceptScore W2904062731C98274493 @default.
• W2904062731 hasFunder F4320332200 @default.
• W2904062731 hasIssue "4" @default.
• W2904062731 hasLocation W29040627311 @default.
• W2904062731 hasLocation W29040627312 @default.
• W2904062731 hasLocation W29040627313 @default.
• W2904062731 hasLocation W29040627314 @default.
• W2904062731 hasOpenAccess W2904062731 @default.
• W2904062731 hasPrimaryLocation W29040627311 @default.
• W2904062731 hasRelatedWork W1532617462 @default.
• W2904062731 hasRelatedWork W2059346471 @default.
• W2904062731 hasRelatedWork W2085438061 @default.
• W2904062731 hasRelatedWork W2398000750 @default.
• W2904062731 hasRelatedWork W2593513173 @default.
• W2904062731 hasRelatedWork W2611972836 @default.
• W2904062731 hasRelatedWork W2959474424 @default.
• W2904062731 hasRelatedWork W3012381399 @default.
• W2904062731 hasRelatedWork W3030177861 @default.
• W2904062731 hasRelatedWork W4256406638 @default.
• W2904062731 hasVolume "4" @default.
• W2904062731 isParatext "false" @default.
• W2904062731 isRetracted "false" @default.

• next